Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:747-754

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinto, Y. M.
Right arrow Articles by Paul, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinto, Y. M.
Right arrow Articles by Paul, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Diseases
*High Blood Pressure
Hazardous Substances DB
*LOSARTAN POTASSIUM
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression

(Hypertension. 2000;36:747.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor ß1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat

Yigal M. Pinto; Sara-Joan Pinto-Sietsma; Tobias Philipp; Sonja Engler; Peter Koßmehl; Berthold Hocher; Heike Marquardt; Svenja Sethmann; Roland Lauster; Hans-Joachim Merker; Martin Paul

From the Department of Clinical Pharmacology and Toxicology (Y.M.P., S.-J.P.-S., T.P., S.E., P.K., H.M., H.-J.M., M.P.), Benjamin Franklin Medical Center, Freie Universität Berlin, Berlin, Germany; Deutsches Rheumaforschungszentrum Berlin (S.S., R.L.), Berlin, Germany; and Department of Internal Medicine (B.H.), Humboldt University, Berlin, Germany.

Correspondence to Yigal M. Pinto, MD, PhD, and Martin Paul, MD, Department of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Garystrasse 5, Berlin, 14195 Germany. E-mail y.m.pinto{at}thorax.azg.nl

Abstract—Angiotensin II recruits transforming growth factor ß1 (TGFß1) and is related to left ventricular fibrosis. However, it is unclear whether chronic in vivo reduction in left ventricular TGFß1 expression blunts fibrosis and improves outcome in angiotensin II–dependent hypertension. Four-week-old male hypertensive TGR(mRen2)27 (Ren2) rats received either normal food, low-dose losartan (0.5 mg · kg-1 · d-1), or tranilast (a nonspecific TGFß inhibitor; 400 mg · kg-1 · d-1) (n=10 for each group) for 12 weeks and were compared with Sprague-Dawley control rats. The effect of tranilast on survival was evaluated in 34 additional untreated homozygous Ren2 rats. Tranilast or low-dose losartan did not lower blood pressure. However, the increase in left ventricular weight (Ren2 versus SD 3.1±0.16 versus 2.1± 0.06 mg/g body wt; P<0.05) was significantly (P<0.05) blunted by both tranilast (2.7±0.05) and losartan (2.7±0.07). Both drugs prevented the increase in left ventricular TGFß1 mRNA and fibronectin mRNA and blunted the increase in hydroxyproline content and the increase in perivascular fibrosis. The perivascular fibrosis score correlated significantly with the level of expression of TGFß1 (r=0.62; P=0.019). In situ hybridization demonstrated increases in TGFß1 mRNA, predominantly in perivascular and nonmyocyte areas. Both drugs did not prevent the decrease in systolic or diastolic dP/dt, but tranilast significantly improved the survival of untreated Ren2 rats (P=0.029). In conclusion, TGFß1 mRNA expression is increased predominantly in nonmyocyte regions in the hypertrophied left ventricle in this angiotensin II–dependent model of hypertension. This increase is probably due to high angiotensin II levels rather than to hypertension. This is the first study to suggest that chronic inhibition of TGFß1 expression attenuates left ventricular hypertrophy and fibrosis, even without lowering blood pressure.


Key Words: hypertension, experimental • hypertrophy • transforming growth factors • fibrosis




This article has been cited by other articles:


Home page
JNMHome page
M. E. Campian, H. J. Verberne, M. Hardziyenka, K. de Bruin, M. Selwaness, M. J.B. van den Hoff, J. M. Ruijter, B. L.F. van Eck-Smit, J. M.T. de Bakker, and H. L. Tan
Serial Noninvasive Assessment of Apoptosis During Right Ventricular Disease Progression in Rats
J. Nucl. Med., August 1, 2009; 50(8): 1371 - 1377.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
G. Dell'Omo, G. Penno, L. Pucci, D. Lucchesi, S. Del Prato, and R. Pedrinelli
Lack of association between TGF-{beta}-1 genotypes and microalbuminuria in essential hypertensive men
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1864 - 1869.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. T. Cicila, E. E. Morgan, S. J. Lee, P. Farms, S. Yerga-Woolwine, E. J. Toland, R. S. Ramdath, K. Gopalakrishnan, K. Bohman, A. L. Nestor-Kalinoski, et al.
Epistatic Genetic Determinants of Blood Pressure and Mortality in a Salt-Sensitive Hypertension Model
Hypertension, April 1, 2009; 53(4): 725 - 732.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. F. Duisters, A. J. Tijsen, B. Schroen, J. J. Leenders, V. Lentink, I. van der Made, V. Herias, R. E. van Leeuwen, M. W. Schellings, P. Barenbrug, et al.
miR-133 and miR-30 Regulate Connective Tissue Growth Factor: Implications for a Role of MicroRNAs in Myocardial Matrix Remodeling
Circ. Res., January 30, 2009; 104(2): 170 - 178.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Whaley-Connell, J. Habibi, S. A. Cooper, V. G. DeMarco, M. R. Hayden, C. S. Stump, D. Link, C. M. Ferrario, and J. R. Sowers
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E103 - E109.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. J. Kelly, Y. Zhang, K. Connelly, A. J. Cox, J. Martin, H. Krum, and R. E. Gilbert
Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2860 - H2869.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. W.M. Schellings, M. Baumann, R. E.W. van Leeuwen, R. F.J.J. Duisters, S. H.P. Janssen, B. Schroen, C. J. Peutz-Kootstra, S. Heymans, and Y. M. Pinto
Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 Rats
Hypertension, March 1, 2006; 47(3): 467 - 474.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Martin, D. J. Kelly, S. A. Mifsud, Y. Zhang, A. J. Cox, F. See, H. Krum, J. Wilkinson-Berka, and R. E. Gilbert
Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-{beta}
Cardiovasc Res, February 15, 2005; 65(3): 694 - 701.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Pokharel, P. P. van Geel, U. C. Sharma, J. P.M. Cleutjens, H. Bohnemeier, X.-L. Tian, H. Schunkert, H. J.G.M. Crijns, M. Paul, and Y. M. Pinto
Increased Myocardial Collagen Content in Transgenic Rats Overexpressing Cardiac Angiotensin-Converting Enzyme Is Related to Enhanced Breakdown of N-Acetyl-Ser-Asp-Lys-Pro and Increased Phosphorylation of Smad2/3
Circulation, November 9, 2004; 110(19): 3129 - 3135.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. J. Kelly, Y. Zhang, R. Gow, and R. E. Gilbert
Tranilast Attenuates Structural and Functional Aspects of Renal Injury in the Remnant Kidney Model
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2619 - 2629.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. Schroen, S. Heymans, U. Sharma, W. M. Blankesteijn, S. Pokharel, J. P.M. Cleutjens, J. G. Porter, C. T.A. Evelo, R. Duisters, R. E.W. van Leeuwen, et al.
Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy
Circ. Res., September 3, 2004; 95(5): 515 - 522.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Rosenkranz
TGF-{beta}1 and angiotensin networking in cardiac remodeling
Cardiovasc Res, August 15, 2004; 63(3): 423 - 432.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Peng, O. A. Carretero, D. R. Brigstock, N. Oja-Tebbe, and N.-E. Rhaleb
Ac-SDKP Reverses Cardiac Fibrosis in Rats With Renovascular Hypertension
Hypertension, December 1, 2003; 42(6): 1164 - 1170.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Hein, E. Arnon, S. Kostin, M. Schonburg, A. Elsasser, V. Polyakova, E. P. Bauer, W.-P. Klovekorn, and J. Schaper
Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms
Circulation, February 25, 2003; 107(7): 984 - 991.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Akiyama-Uchida, N. Ashizawa, A. Ohtsuru, S. Seto, T. Tsukazaki, H. Kikuchi, S. Yamashita, and K. Yano
Norepinephrine Enhances Fibrosis Mediated by TGF-{beta} in Cardiac Fibroblasts
Hypertension, August 1, 2002; 40(2): 148 - 154.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Pokharel, S. Rasoul, A. J.M. Roks, R. E.W. van Leeuwen, M. J.A. van Luyn, L. E. Deelman, J. F. Smits, O. Carretero, W. H. van Gilst, and Y. M. Pinto
N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts
Hypertension, August 1, 2002; 40(2): 155 - 161.
[Abstract] [Full Text] [PDF]